HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.106.037937v1 48/8/1357    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Costantini, D. L. Articles by Reilly, R. M. Search for Related Content PubMed PubMed Citation Articles by Costantini, D. L. Articles by Reilly, R. M.

¹¹¹In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer

¹ Departments of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada; ² Department of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom; ³ Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; and ⁴ Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada

Correspondence: For correspondence or reprints contact: Raymond M. Reilly, PhD, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, Ontario, Canada M5S 3M2. E-mail: raymond.reilly{at}utoronto.ca

The cytotoxicity and tumor-targeting properties of the anti-HER2/neu monoclonal antibody trastuzumab modified with peptides (CGYGPKKKRKVGG) harboring the nuclear localization sequence ([NLS] italicized) of simian virus 40 large T-antigen and radiolabeled with ¹¹¹In were evaluated. Methods: Trastuzumab was derivatized with sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) for reaction with NLS-peptides and labeled with ¹¹¹In using diethylenetriaminepentaacetic acid (DTPA). The immunoreactivity of ¹¹¹In-NLS-trastuzumab was determined by its ability to displace the binding of trastuzumab to SK-BR-3 human breast cancer (BC) cells. Cellular uptake and nuclear localization were evaluated in SK-BR-3, MDA-MB-361, and MDA-MB-231 BC cells, expressing high, intermediate, or very low levels of HER2/neu, respectively, by cell fractionation and confocal microscopy. Biodistribution and nuclear uptake were compared in athymic mice bearing MDA-MB-361 xenografts. The cytotoxicity of ¹¹¹In-trastuzumab and ¹¹¹In-NLS-trastuzumab was studied by clonogenic assays, and DNA damage was assessed by probing for phosphorylated histone H2AX (H2AX) foci. Results: The dissociation constant for binding of ¹¹¹In-NLS-trastuzumab to SK-BR-3 cells was reduced <3-fold compared with that of ¹¹¹In-trastuzumab, demonstrating relatively preserved receptor-binding affinity. The receptor-mediated internalization of ¹¹¹In-trastuzumab in SK-BR-3, MDA-MB-361, and MDA-MB-231 cells increased significantly from 7.2% ± 0.9%, 1.3% ± 0.1%, and 0.2% ± 0.05% to 14.4% ± 1.8%, 6.3% ± 0.2%, and 0.9% ± 0.2% for ¹¹¹In-NLS-trastuzumab harboring 6 NLS-peptides, respectively. NLS-trastuzumab localized in the nuclei of BC cells, whereas unmodified trastuzumab remained surface-bound. Conjugation of ¹¹¹In-trastuzumab to NLS-peptides did not affect its tissue biodistribution but promoted specific nuclear uptake in MDA-MB-361 xenografts (2.4–2.9 %ID/g [percentage injected dose per gram] for ¹¹¹In-NLS-trastuzumab and 1.1 %ID/g for ¹¹¹In-trastuzumab). ¹¹¹In-NLS-trastuzumab was 5- and 2-fold more potent at killing SK-BR-3 and MDA-MB-361 cells than ¹¹¹In-trastuzumab, respectively, whereas toxicity toward MDA-MB-231 cells was minimal. ¹¹¹In-NLS-trastuzumab was 6-fold more effective at killing SK-BR-3 cells than unlabeled trastuzumab. Formation of H2AX foci occurred in a greater proportion of BC cells after incubation with ¹¹¹In-NLS-trastuzumab compared with ¹¹¹In-trastuzumab or unlabeled trastuzumab. Conclusion: NLS-peptides routed ¹¹¹In-trastuzumab to the nucleus of HER2/neu-positive human BC cells, rendering the radiopharmaceutical lethal to the cells through the emission of nanometer–micrometer range Auger electrons. The greater cytotoxic potency of ¹¹¹In-NLS-trastuzumab compared with unlabeled trastuzumab in vitro and its favorable tumor-targeting properties in vivo suggest that it could be an effective targeted radiotherapeutic agent for HER2/neu-amplified BC in humans.

Key Words: breast cancer • trastuzumab (Herceptin) • ¹¹¹In • nuclear translocation • Auger electrons

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				X. Liu, Y. Wang, K. Nakamura, S. Kawauchi, A. Akalin, D. Cheng, L. Chen, M. Rusckowski, and D. J. Hnatowich Auger Radiation-Induced, Antisense-Mediated Cytotoxicity of Tumor Cells Using a 3-Component Streptavidin-Delivery Nanoparticle with 111In J. Nucl. Med., April 1, 2009; 50(4): 582 - 590. [Abstract] [Full Text] [PDF]

				D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate J. Nucl. Med., September 1, 2008; 49(9): 1498 - 1505. [Abstract] [Full Text] [PDF]

				S. Lindegren, S. Frost, T. Back, E. Haglund, J. Elgqvist, and H. Jensen Direct Procedure for the Production of 211At-Labeled Antibodies with an {varepsilon}-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate J. Nucl. Med., September 1, 2008; 49(9): 1537 - 1545. [Abstract] [Full Text] [PDF]

				Z. Cai, Z. Chen, K. E. Bailey, D. A. Scollard, R. M. Reilly, and K. A. Vallis Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to 111In-DTPA-hEGF J. Nucl. Med., August 1, 2008; 49(8): 1353 - 1361. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]